Study |
Type of data |
Exposure measurement |
Outcome assessment |
Adjustment |
Andersen (vs diclofenac), 2016
|
retrospective cohort (claims database)
|
niformation on drug use was acquired from the National Prescription Register (Register of Medicinal Product Statistics)
|
National Hospital Register was used to identify all records of induced abortion [O04, O05 and O06 according to the International Classification of Diseases 10th edition Danish revision (ICD10)] and all records of miscarriage (ICD10-codes O021 and O03)
|
maternal age (five categories: 20, 20–24, 25–29, 30–34, C35 years), household income (as quartiles), educational length in months (four categories: B143, 144–155, 156–179, C180 months), number of previous miscarriages (four categories: 0, 1, 2, C3) and year of outcome (three categories: 1997–2001, 2002–2006, 2007–2010).
|
Andersen (vs unexposed), 2016
|
retrospective cohort (claims database)
|
niformation on drug use was acquired from the National Prescription Register (Register of Medicinal Product Statistics)
|
National Hospital Register was used to identify all records of induced abortion [O04, O05 and O06 according to the International Classification of Diseases 10th edition Danish revision (ICD10)] and all records of miscarriage (ICD10-codes O021 and O03)
|
maternal age (five categories: 20, 20–24, 25–29, 30–34, C35 years), household income (as quartiles), educational length in months (four categories: B143, 144–155, 156–179, C180 months), number of previous miscarriages (four categories: 0, 1, 2, C3) and year of outcome (three categories: 1997–2001, 2002–2006, 2007–2010).
|
Auffret, 2016
|
prospective cohort
|
Pregnant women who had contacted a pharmacovigilance centre (CRPV) between 1 January 1988 and 31 December 2012. Inclusion criteria: 1) exposure to misoprostol before 13WG 2) first contact with the CRPV before 22 weeks of gestation (WG) 3) known pregnancy outcome and examinable newborn or fetus.
|
mothers' report confirmed by physician
|
|
Barbero, 2011
|
prospective cohort
|
Interview of mothers during consultation in LSF
|
Mother's report confirmed by physician in case of malformation
|
age, niveau de scolarité, activité professionnelle
|
Brasil, 2000
|
case control
|
Standard maternal report
|
Standard maternal report
|
maternal age, birth weight
|
Dal Pizzol, 2008
|
retrospective cohort
|
Maternal interview. The specific use of products to induce menstruationwas investigated with the question: “To discoverwhether you were pregnant, did you use some kindof drug for your period to come?”.
|
Mother’s medical chart. Congenital anomalies were classified according to the 9th Revision of the International Classification of Diseases (ICD-9)
|
yes but factors were not clearly explained
|
Opaleye, 2010
|
case control
|
Maternal interviews by a trained team by means of a structured questionnaire based on the Latin American Collaborative Study of Congenital Malformations
|
The search for newborns who met the criteria for inclusion of the sample was given through daily phone calls to each of the hospitals.
|
no specified
|
Orioli, 2000
|
case control
|
mother's interwiew by a qualified paediatrician in the puerperium.
|
not specified
|
not specified
|
Pastuszak, 1998
|
case control
|
misoprostol treatment (indication, route, dose, duration, and complications) was extracted from the records by personnel using a standardized form
|
clinical geneticists
|
|
Vargas, 2000
|
case control
|
Structured maternal questionnaire. Possible pregnancy termination attempts and misoprostol use were interrogated by open, semi-open, or closed questions.
|
Not specified
|
Matching according to maternal age (± 2 year) and parity
|
Vauzelle, 2013
|
prospective cohort
|
Health care professionales are asked to answer standardized questions referring to specific exposure
|
a month after he estimated date of birth
|
|